Press Releases

Beta Bionics, Inc. today announced that Martha G. Aronson and Sean D. Carney have been appointed to the Company’s Board of Directors effective immediately. “We are all very excited and feel extremely fortunate, at Beta Bionics, to have Martha and Sean join our Board of Directors. Their experience and expertise in the commercial and financial aspects of our business are substantial, and will be invaluable assets to our Board and management team going forward,” said Ed Damiano, President and CEO of Beta Bionics. 

Beta Bionics Logo

Beta Bionics, Inc. announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its investigational iLet Bionic Pancreas System.

Beta Bionics Logo

​Beta Bionics, Inc. announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis-related diabetes (CFRD).

beta bionics convatec.jpg

​ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world-class infusion sets available for use with the iLet Bionic Pancreas System.

Beta Bionics Logo

​Beta Bionics, Inc. announced that the company has completed a $63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million.

beta bionics zeal&.jpg

Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet® bionic pancreas using dasiglucagion.

beta bionics zeal&.jpg

First Home-Use Trial of the Bihormonal iLet With Dasiglucagon in a Pre-Filled, Commercial Ready, Pump Cartridge

May 22, 2019

​This home-use clinical trial is being conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital.

Beta Bionics Logo

​Beta Bionics announces that the company has now completed its Series B equity financing, which has reached a total of $63 million.  

Beta Bionics Logo

Beta Bionics Awarded Up to $2 Million NIH Small Business Innovation Research (SBIR) Grant

October 9, 2018

Beta Bionics has been awarded up to $2 million in the form of an SBIR grant (R44-DK120234) by the NIDDK, which is part of the U.S. National Institutes of Health (NIH).

beta bionics (1)-01.jpg

Beta Bionics has so far raised $50 million of a Series B equity financing.

beta bionics (1)-01.jpg

The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM

beta bionics (1)-01.jpg

​Beta Bionics has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system in adults and children with T1D.

beta bionics zeal&.jpg

Zealand Pharma boosts collaboration with Beta Bionics to advance development of its dasiglucagon in the iLet.

beta bionics zeal&.jpg

Zealand Pharma and Beta Bionics announce a positive outcome from the Phase 2a clinical safety trial using dasiglucagon in the dual-hormone artificial pancreas system, developed at Boston University and licensed to Beta Bionics. 

bu.jpg

​The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days.

MGH Logo

The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days.

beta bionics zeal&.jpg

Copenhagen, 13 December 2016 – Zealand Pharma (Zealand) today announced that it has dosed the first patients in its Phase IIa clinical trial with dasiglucagon1 in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics.

beta bionics zeal&.jpg

Copenhagen, Denmark and Boston, Massachusetts, 10 June 2016 – Zealand Pharma, or Zealand, a peptide drug discovery, design and development company, and Beta Bionics, a medical technology company, jointly announced today that they have engaged in a collaboration. 

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

© 2020 Beta Bionics, Inc. Beta Bionics® and iLet® are registered trademarks of Beta Bionics, Inc. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.